Roche closes acquisition of LumiraDx’s Point of Care technology
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
The agreement sets terms under which POC will manufacture the product or receive royalties
HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Subscribe To Our Newsletter & Stay Updated